The webinar, LTBI: New guidelines from the WHO; getting away from INH, examines various treatment regimens for latent tuberculosis infection – essential in preventing TB before the disease progresses.
The webinar, LTBI: New guidelines from the WHO; getting away from INH, examines various treatment regimens for latent tuberculosis infection (LTBI) – essential in preventing TB before the disease progresses.
TB can live dormant in a person and develop into active disease in the future. The risk of progression to active TB is considerably higher in individuals who belong to high-risk population groups, such as those with HIV or diabetes.
Originally released for Union members only, the webinar is now available to the public.
Professor Dick Menzies from the Montreal Chest Institute and McGill TB Centre shares what is new in the World Health Organization’s (WHO) guidelines on LTBI, and also discusses alternatives to using isoniazid therapy (INH).
Prof Menzies discusses several options for treating LTBI including: six months INH (the WHO’s primary recommendation); nine months INH; three months INH and Rifampin; three months once weekly INH and Rifapentine; and three or four months Rifampin only. In all cases the aim is to understand how each treatment regimen compares to the recommended INH regimen(s) in terms of safety and completion, as well as efficacy to prevent TB.
Watch the ‘LTBI: New guidelines from the WHO; getting away from INH’ webinar now:
Exclusive webinars hosted by international experts in their fields are one of the many benefits Union members enjoy. An archive of all webinars covering a range of topics are available to members on Member Services.
The next members-only webinar is titled Double Trouble: diabetes and tuberculosis and will be held on Thursday, 23 May 2019, 14:00-15:00 CET. Diabetes mellitus (DM) increases the risk of TB, and persons with dual disease have worse TB treatment outcomes compared with persons with only TB. TB may also lead to hyperglycaemia and result in overt diabetes in susceptible persons. The webinar will address these issues and discuss best practices for ensuring positive outcomes for this high-risk group. Members can register to secure a place.
Find out more about becoming a member of The Union to access these exclusive webinars. Members also benefit from various professional opportunities and resources, including a subscription to the International Journal of Tuberculosis and Lung Disease.